The Menarini Group products

FELEZONEXOR (SL-801) is a novel, oral, small-molecule reversible inhibitor of exportin-1 (XPO1), a key nuclear transport protein. XPO1 is overexpressed by many cancers, leading to mislocalization of key tumor suppressors and growth-regulatory proteins in the cytoplasm. FELEZONEXOR is currently being tested as a potential treatment for patients with solid tumors.

MEN1309 is an antibody-drug conjugate (ADC) constituted by a fully human IgG1 antibody conjugated through a cleavable linker to a cytotoxic agent (a maytansin derivative, DM4), responsible for its antitumor activity. The target antigen, CD205, is highly expressed in a wide range of both solid and hematological cancer cells. Once MEN1309 binds its target, the MEN1309/CD205 complex is rapidly internalized in antigen expressing cells where it can exert its cytotoxic activity. MEN1309 is currently being tested as a potential treatment for patients with solid tumors.

NEXPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor. XPO1 is a nuclear exporter protein that transport from the nucleus to the cytoplasm several proteins, including tumor suppressors, oncogenes, and proteins involved in governing cell growth; it is often overexpressed, and its function mis-regulated in several types of cancers. By inhibiting the XPO1 protein, tumor suppressors proteins buildup in the nucleus of malignant cells and reduce levels of oncogene products which drive cell proliferation. This ultimately leads to cell cycle arrest and death of cancer cells by apoptosis.

Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER+/ HER2- advanced or metastatic breast cancer.

MEN1703 is a dual kinase inhibitor targeting PIM (PIM1, PIM2, PIM 3) and FLT3 kinases. FLT3 internal tandem duplication (FLT3-ITD) is one of the most common genetic lesions in acute myeloid leukemia patients (AML) and is associated with a poor prognosis. PIM kinases are thought to be one of the major drivers of the resistance phenotype to FLT3 inhibitors and their inhibition in relapsed samples restores cell sensitivity to FLT3 inhibitors these agents.